ESTRO 2022 - Abstract Book

S998

Abstract book

ESTRO 2022

Acute toxicity is summarized in table 1. No patient experienced ≥ G3 acute toxicity. No significant differences in toxicity were found between the different RT techniques. G2 skin toxicity was experienced in 13% of pts with SIB and 8% without SIB. Significant increase of G1-G2 skin toxicity and dysphagia were found in pts treated on chest wall with post-mastectomy reconstruction (as summarized in table 2).

Conclusion Locoregional HRT is feasible with low acute toxicity without significant differences in toxicity between the different RT techniques. Longer follow-up is needed to evaluate late toxicity and local control in the different subgroups of patients.

PO-1178 Outcome of male breast cancer patients at an academic university hospital in India

D. Chakrabarti 1 , A. Ghosh 1 , M. Verma 1 , D. Kukreja 1 , N. Akhtar 2 , S. Rajan 2 , S. Qayoom 3 , P. Ramakant 4 , V. Kumar 2 , K. Srivastava 1 , R. Gupta 1 , M.L. Bhatt 1 1 King George's Medical University, Radiotherapy, Lucknow, India; 2 King George's Medical University, Surgical Oncology, Lucknow, India; 3 King George's Medical University, Pathology, Lucknow, India; 4 King George's Medical University, Endocrine Surgery, Lucknow, India Purpose or Objective Male breast cancer is a rare disease accounting for less than 1 % of all breast cancer cases worldwide. Most of our knowledge about them is based on retrospective datasets. Materials and Methods This retrospective cohort study included all patients of invasive male breast cancer treated at the radiotherapy department of a tertiary care academic university hospital in India between 2012 and 2020. Records were identified from a prospectively maintained database. Clinicopathological parameters, treatment details, recurrence patterns, and survival were determined. Results Twenty-three patients were included. The median age was 55 years. Most patients were UICC TNM composite stage III (74%) and node-positive (78%) with Scarff-Bloom-Richardson grade II (52%). One patient presented with metastatic disease upfront. Sixteen patients (70%) were estrogen receptor (ER) positive. Lymphovascular space invasion (LVSI) and perineural invasion (PNI) were present in 65% and 26% of patients respectively. The most common chemotherapy timing was adjuvant (61%), and the most commonly used regimen consisted of a triplet of 5-fluorouracil, an anthracycline (doxorubicin or epirubicin), and cyclophosphamide (FAC or FEC, 57%). Twenty-two patients underwent surgery (two lumpectomies, one wide local excision, 17 mastectomies) and subsequent radiotherapy to a dose of 42.6 Gy in 16 fractions. At a median follow up of 53 months (95% CI 47-67 months), three patients had died. Nine patients had local or distant failures (four bone metastases, one lung metastasis, four locoregional recurrences). The five-year disease-free survival (DFS) was 57%, and five-year overall survival (OS) was 87%.